One of the key downregulators of T cell activation is CD152 (CTLA-4). Mice genetically de®cient in CD152 (cd152 ±/± mice) develop massive expansion of both CD4 + and CD8 + T cells as well as increased numbers of splenic Ig-secreting cells and serum Ig levels. To determine the dependence of the lymphoproliferation and B cell hyperactivity on MHC class II (MHCII), MHCII-de®cient (mhcii ±/± ) cd152 ±/± mice were generated. Compared to that in their mhcii +/+ counterparts, expansion of CD4 + cells in mhcii ±/± cd152 ±/± mice was markedly attenuated. Nonetheless, expansion of CD8 + cells was identical in both sets of mice, demonstrating that the effects of CD152 de®ciency on CD4 + cells can quantitatively be dissociated from those on CD8 + cells, and pointing to a critical downregulatory role for CD152 in MHCII-independent CD8 + cell activation in vivo. B cell hyperactivity also developed in mhcii ±/± cd152 ±/± mice, albeit in a manner less rapid and less intense than that in their mhcii +/+ counterparts, demonstrating an underlying MHCII-independent diathesis to B cell dysregulation and pointing to a critical downregulatory role for CD152 in MHCIIindependent B cell activation in vivo. When human DQ8 was introduced as a transgene into mhcii ±/± cd152 ±/± mice, B cell hyperactivity was restored to levels observed in mhcii +/+ cd152 ±/± mice, pointing to a critical downregulatory role for CD152 in MHCII-dependent B cell activation in vivo superimposed upon its downregulatory role on MHCII-independent B cell activation.
Introduction
T cells play a vital and central role in the adaptive immune response. On the one hand, insuf®cient T cell activation may result in clinically signi®cant immunode®ciency, with the host being incapable of adequately combating microbial pathogens. On the other hand, excessive T cell activation can result in clinically signi®cant autoimmunity, potentially involving any organ system. Accordingly, not only must the host be capable of responding quickly and vigorously to antigenic stimulation, but the host must also be capable of tightly controlling such responses and maintaining T cell activation in check.
One of the critical downregulators of T cell activation is CD152 (CTLA-4). In resting T cells, CD152 is predominantly expressed intracellularly with only limited cell surface expression (1) . Following TCR engagement, intracellular and the limited cell surface CD152 focus to the sites of TCR engagement (2) , with greater strength of the TCR signal resulting in greater surface accumulation of CD152 (3) . CD152 mRNA levels are upregulated within hours (4) , and cell surface CD152 expression greatly increases within days (5, 6) , although intracellular CD152 still predominates (7) . At least two independent intracellular signaling pathways mediate CD152 upregulation (8) .
CD80 (B7.1) and CD86 (B7.2), expressed by cells capable of antigen presentation (e.g. monocytes, macrophages, dendritic cells, B cells), are the natural ligands for CD152 (9±12). Engagement of CD152 delivers a direct inhibitory signal and also sequesters CD80/CD86, thereby indirectly impeding CD28-mediated activation (13, 14) . At least part of the inhibition is due to increased indoleamine 2,3-deoxygenase activity by dendritic cells with consequent increased catabolism of tryptophan (15) . The net result of CD152 engagement is inhibition of activation-induced upregulation of membrane lipid raft expression (16) and arrest of T cells in the G0/G1 phase of the cell cycle (17, 18) .
Blockade of CD152 engagement has a myriad of biologic consequences. On the one hand, treatment with soluble anti-CD152 mAb results in enhanced in vitro T cell proliferation and IL2 production (5, 6, 19) . Similar blockade of CD152 in vivo enhances expansion of antigen-speci®c T cells, promotes protective immunity against parasitic infection, blocks immunostimulatory' chronic graft-versus-host disease and augments development of anti-tumor immunity (20±23). On the other hand, in vivo blockade of CD152, rather than being bene®cial, may be deleterious to the host, in that it accelerates and exacerbates onset and severity of experimental autoimmune encephalomyelitis (EAE) and autoimmune diabetes (24±26) and confers susceptibility to EAE in otherwise resistant mice (27) . Indeed, engagement of CD152 is crucial to development and/or maintenance of tolerance in vivo (28, 29) , and the potent suppressor effects of CD4 + CD25 + regulatory T cells are substantially mediated via CD152 (30, 31) .
Mice genetically de®cient in CD152 (cd152 ±/± mice) spontaneously develop massive systemic T lymphoproliferation with in®ltration of numerous vital organs by lymphocytes and in¯ammatory cells (32±34). Thymocyte development, including negative and positive selection, is normal in cd152 ±/± mice (35, 36) , indicating that the physiologic defect is in control of peripheral T cell activation rather than in central T cell development. Since the accelerated T cell activation, lymphoproliferation and mortality are markedly attenuated in TCRtransgenic cd152 ±/± mice with highly limited T cell repertoires (36±39), it is likely that the proliferating T cells in these mice respond to self antigens and/or to highly prevalent environmental antigens. The fact that the activated T cells in nontransgenic cd152 ±/± mice manifest a diverse and unbiased TCR repertoire (40) indicates that no individual self or environmental antigen is uniquely driving the pathologic response.
The rami®cations of CD152 de®ciency for B cells in vivo are less well understood. Increased B cell numbers and circulating Ig levels, as well as upregulation of B cell surface CD86, have been reported in cd152 ±/± mice (32, 34) . This B cell hyperactivity may be secondary to excessive CD4 + cellmediated help, inasmuch as treatment of cd152 ±/± mice with a depleting anti-CD4 mAb blocks the B lymphocytosis (34) . Since CD4 + T cell-mediated help is predominantly MHC class II (MHCII)-restricted and antibody responses to T celldependent antigens are profoundly blunted in MHCII-de®cient (mhcii ±/± ) mice (41, 42) , one might predict that numbers of Igsecreting cells (IgSC) and circulating Ig levels would be (near-) normal in MHCII-de®cient cd152 ±/± mice. Moreover, the widespread activation and expansion of CD8 + cells in cd152 ±/± mice is also greatly attenuated by depletion of CD4 + cells (34) , suggesting that dysregulation of CD4 + cells is also vital to dysregulation of CD8 + cells. Accordingly, one might predict that CD8 + cell activation and expansion in MHCII-de®cient cd152 ±/± mice would be, at most, very limited.
In this report, we demonstrate that these predictions are each incorrect. CD8 + cell activation and expansion in MHCIIde®cient cd152 ±/± mice are as dramatic as they are in MHCIIintact cd152 ±/± mice. Furthermore, B cell hyperactivity also develops in MHCII-de®cient cd152 ±/± mice over time, although in a manner less rapid and less intense than that in corresponding MHCII-intact mice. Thus, CD152 plays a vital role in downregulating`spontaneous' MHCII-independent CD8 + cell expansion and B cell hyperactivity. Moreover, introduction of human MHCII into mhcii ±/± cd152 ±/± mice restores the more rapid kinetics and greater intensity of B cell hyperactivity, demonstrating a vital role for CD152 in downregulating both spontaneous' MHCII-dependent as well as`spontaneous' MHCII-independent B cell hyperactivity.
Methods

General
All reported studies were approved by the University of Southern California (USC) Institutional Animal Care and Use Committee.
Mice
All mice were housed at USC in a single speci®c pathogenfree room. MHCII-intact (mhcii +/+ ) cd152 +/± mice bearing a C57Bl/6 (B6) background (35) were propagated by mating with B6 (cd152 +/+ ) mice and screening the progeny for cd152 heterozygosity (see below). MHCII-de®cient (mhcii ±/± ) cd152 +/± mice were generated by ®rst crossing mhcii +/+ cd152 +/± mice with Ab0 mice (mhcii ±/± cd152 +/+ ) (41, 43) and selecting for cd152 heterozygosity. The resulting mhcii +/± cd152 +/± mice were backcrossed to Ab0 mice and selected for cd152 heterozygosity and the absence of MHCII (see below).
To reconstitute mhcii ±/± cd152 ±/± mice with human MHCII, mhcii ±/± cd152 +/± mice were crossed with Ab0-DQ8 mice (mhcii ±/± dq8 +/+ cd152 +/+ ; de®cient for murine endogenous MHCII and homozygous for a transgenic fragment containing both DQA*0301 and DQB*0302 genes) (44) . The progeny (all mhcii ±/± dq8 +/± ) were selected for cd152 heterozygosity and were backcrossed to Ab0-DQ8 mice. Progeny from this backcross that were cd152 +/± were screened for dq8 homozygosity by mating to B6 mice and testing the progeny for dq8 by PCR (see below). At least 12 pups from a given cd152 +/± parent were tested, and cd152 +/± parents were deemed to be dq8 +/+ if all b12 pups bore dq8.
Assignment of cd152 genotype cd152 genotype was determined by PCR. Small clippings of mouse tails were digested for >4 h at 56°C by proteinase K in Tris/EDTA/SDS buffer followed by phenol/chloroform extraction of genomic DNA. Genomic DNA was PCR-ampli®ed for 42±45 cycles each at 95°C for 1 min, 60°C for 1 min and 72°C for 1 min. The primer sequences used were: 5¢-CCAGAACCATGCCCGGATTCTGACTTC-3¢ (cd152-intact sense), 5¢-CCAAGTGCCCAGAGGGGCTGCTAAA-3¢ (cd152-de®cient sense), 5¢-AAACAACCCCAAGCTAACTGCGACA-AGG-3¢ (anti-sense). The PCR products were subjected to electrophoresis in 1.5% agarose gels containing ethidium bromide, and bands were visualized under UV light. Band sizes for cd152-intact and cd152-de®cient were~90 and 180 bp respectively. (41, 42) , and staining PBMC for surface CD4 readily discriminated visually between the CD4-low phenotype (mhcii ±/± genotype) and CD4-high phenotype (mhcii +/± or mhcii +/+ genotypes) ( Fig. 1) . Accordingly, the ®rst step in assignment of mhcii genotype was the staining of PBMC for surface CD4. (Staining of spleen cells for surface I-A b was always performed in sacri®ced mice to con®rm the absence of MHCII in CD4-low mice and the presence of MHCII in CD4-high mice.) To distinguish between mhcii +/+ and mhcii +/± genotypes among CD4-high mice, PCR was next performed to detect the neo insertion. (PCR alone cannot distinguish among all three mhcii genotypes, since a PCR product band indicative of the neo insertion would be detected in both mhcii +/± and mhcii ±/± mice.) The primer sequences used were: 5¢-GGATCGGCCATTGAACAAG-3¢ (sense), 5¢-CACCATGATATTCGGCAAGC-3¢ (anti-sense). Band size for neo was~600 bp.
Detection of dq8
The presence of both DQ8a and DQ8b were detected by PCR using the following primer sequences: 5¢-GAAGA-CATTGTGGCTGACCATGTTGCC-3¢ (DQ8a sense), 5¢-AG-CACAGCGATGTTTGTCAGTGCAAATTGCGG-3¢ (DQ8a anti-sense), 5¢-AGGATTTGGTGTWCCAGTTTAAGGGCAT-3¢ (DQ8b sense), 5¢-TGCAAGGTCGTGCGGAGCTCCAA-3¢ (DQ8b anti-sense). Band sizes for dq8a and dq8b werẽ 250 and~350 bp respectively.
Cell surface staining
Murine spleen mononuclear cells were isolated by mechanically teasing the spleens followed by Ficoll density gradient centrifugation. The isolated mononuclear cells were single-, double-or triple-stained with appropriate combinations of FITC-, PE-or Cy-Chrome-conjugated mAb speci®c for murine CD3, CD4, CD8, CD44, CD45R (B220), CD62L or I-A b (BD PharMingen, San Diego, CA) and analyzed by¯ow cytometry. Cell debris, as determined by forward-and side-scatter characteristics, was electronically excluded from the analysis. At least 10 000 events were analyzed for each sample.
Serum Ig and spleen IgSC determinations
Mice were bled and/or sacri®ced at the indicated times. Serum was assayed for total IgG and total IgM by ELISA. To do so, 96-well¯at-bottomed plates were coated overnight at 4°C with goat anti-mouse IgG+IgA+IgM antibodies (Zymed (45, 46) . Each plaque-forming cell was taken as an IgSC.
Statistical analysis
All analyses were performed using SigmaStat software (SPSS, Chicago, IL). To achieve normality, the results (cell numbers, cell percentages, Ig levels, IgSC) were log-transformed. Parametric testing between two matched or unmatched groups was performed by the paired or unpaired t-test respectively. Parametric testing among three or more groups was performed by one-way ANOVA. When log-transformation failed to generate normally distributed data or the equal variance test was not satis®ed, non-parametric testing was performed by the Mann±Whitney rank sum test between two groups and by Kruskal±Wallis one-way ANOVA on ranks among three or more groups. Correlations were determined by Pearson product moment correlation for interval data and by Spearman rank order correlation for ordinal data or for interval data which did not follow a normal distribution.
Results
Marked expansion and activation of CD4 + and CD8 + cells in mhcii +/+ cd152 ±/± mice MHCII-intact (mhcii +/+ ) cd152 +/± male and female mice were mated to each other, and the resulting F2 progeny was genotypically +/+, +/± and ±/± for cd152 at the expected 1:2:1 ratio. Since mhcii +/+ cd152 ±/± mice begin to die by 3±5 weeks of age (32, 33, 35 and unpublished observations), we studied 3-week-old mice. Consistent with previous reports (32±34), marked (3-to 4-fold) expansion of T (CD3 + ) cells, with similar expansions of both CD4 + cells and CD8 + cells, developed in mhcii +/+ cd152 ±/± mice compared to cd152 +/+ or cd152 +/± littermates ( Fig. 2A±C ; P < 0.001 for each cell type). Large percentages of both CD4 + and CD8 + cells in mhcii +/+ cd152 ±/± mice displayed an activated (CD44 + 62L ± ) phenotype, whereas far fewer activated CD4 + and CD8 + cells were detected in either mhcii +/+ cd152 +/+ mice (Fig. 3) or mhcii +/+ cd152 +/± mice (data not shown).
Unmitigated CD8 cell expansion and activation with attenuated CD4 cell expansion in mhcii ±/± cd152 ±/± mice
The identity of the antigens to which the activated CD4 + and CD8 + cells respond in cd152 ±/± mice is unknown. Given that these cells manifest a diverse and unbiased TCR repertoire (40) , it is clear that the T cell activation is a polyclonal one. Since in vivo depletion of CD4 + cells from these mice greatly attenuates the widespread activation and expansion of CD8 + cells (34) , dysregulation of CD8 + cells appears to be linked to dysregulation of CD4 + cells. Given the importance of MHCII to CD4 + cell responses, MHCII may play a crucial role in both CD4 + and CD8 + lymphoproliferation.
To formally assess MHCII-dependence of T cell expansion in cd152 ±/± mice, we mated MHCII-de®cient (mhcii ±/± ) cd152 +/± male and female mice with each other, and the resulting F2 progeny was genotypically +/+, +/± and ±/± for cd152 at the expected 1:2:1 ratio. There were considerably (~70%) fewer splenic CD4 + cells in 3-week-old mhcii ±/± cd152 +/+ and mhcii ±/± cd152 +/± mice compared to those in their mhcii +/+ counterparts (compare Fig. 2E with B; P < 0.001 for each comparison), likely due to the absence of MHCII-based positive selection of CD4 + cells (41, 42) . In mhcii ±/± cd152 ±/± mice, the number of CD4 + cells was modestly greater (<2-fold) than those in cd152 +/+ or cd152 +/± littermates (P = 0.012), but the relative expansion was much more limited than that observed in mhcii +/+ cd152 ±/± mice (P < 0.001). Of note, CD4 + cells from all MHCII-de®cient mice (including those with cd152 +/+ or cd152 +/± genotype) displayed an activated phenotype ( Fig. 3 and data not shown), rendering moot the question of whether CD152 de®ciency promotes activation of MHCII-unrestricted CD4 + cells.
The attenuated CD4 + cell expansion in mhcii ±/± cd152 ±/± mice notwithstanding, expansion CD8 + cells in these mice was unimpeded (compare Fig. 2F with C) . Moreover, whereas CD8 + cells from MHCII-de®cient cd152 +/+ or cd152 +/± mice displayed a non-activated phenotype, CD8 + cells from MHCIIde®cient cd152 ±/± mice displayed an activated phenotype similar to that of CD8 + cells from MHCII-intact cd152 ±/± mice (Fig. 3) . This demonstrates that the MHCII-independent increase in CD8 + cells in cd152 ±/± mice is due to persistent CD8 + cell activation rather than to increased survival of resting or quiescent CD8 + cells.
In contrast to the early death of mhcii +/+ cd152 ±/± mice, mhcii ±/± cd152 ±/± mice live into adulthood and can reproduce (unpublished observations). This permitted us to mate mhcii ±/± cd152 +/± mice to mhcii ±/± cd152 ±/± mice, and the resulting pups (50% being cd152 +/± and 50% being cd152 ±/± ) were evaluated at 5 weeks of age. Although CD4 + cells were modestly increased (2-fold) in mhcii ±/± cd152 ±/± mice compared to those in cd152 +/± littermates (P < 0.001, Fig. 2H ), this increase was overwhelmed by the massive expansion (13-fold) of CD8 + cells in the cd152 ±/± mice (P < 0.001, Fig. 2I ). Thus, CD8 + cell activation and expansion is unfettered in the absence of CD152 in MHCII-de®cient hosts, demonstrating a vital downregulatory role for CD152 in MHCII-independent CD8 + cell expansion.
Development of B cell hyperactivity in mhcii ±/± cd152 ±/± mice Concurrent with the exuberant CD4 + and CD8 + cell expansion in 3-week-old mhcii +/+ cd152 ±/± mice, these mice, despite no increase in splenic B (B220 + ) cells, displayed markedly increased numbers of splenic IgSC (~15-fold; P < 0.001) and circulating levels of IgG (~9-fold; P < 0.001) compared to cd152 +/+ or cd152 +/± littermates (Fig. 4A±C) . Circulating IgM levels were also increased~5-fold (P < 0.001, data not shown). In contrast, splenic IgSC and circulating IgG and IgM levels in 3-week-old mhcii ±/± cd152 ±/± mice were not appreciably different from those in their cd152 +/+ or cd152 +/± littermates (Fig. 4E and F and data not shown) . However, by at Pennsylvania State University on February 23, 2013 http://intimm.oxfordjournals.org/ Downloaded from 5 weeks of age, B cell hyperactivity in mhcii ±/± cd152 ±/± was apparent, albeit not as dramatic as that appreciated in mhcii +/+ cd152 ±/± mice. Although no expansion of splenic B (B220 + ) cells in mhcii ±/± cd152 ±/± mice was detected, splenic IgSC numbers had increased~3-fold (P = 0.001), and serum IgG levels were clearly elevated in ®ve of the nine cd152 ±/± mice relative to their cd152 +/± littermates (Fig. 4G±I) . Thus, there is an underlying MHCII-independent diathesis to B cell hyperactivity which CD152 normally controls. Of note, spleen CD8 + cell numbers correlated strongly with serum IgG levels in mhcii ±/± cd152 ±/± mice (Fig. 4J) , suggesting that the increase in each was being driven by a common trigger (such as the MHCII-unrestricted CD4 + cells) and/or that the B cell hyperactivity was actually promoted (at least in part) by activated CD8 + cells.
Quantitative restoration of B cell hyperactivity in Ab0-DQ8.cd152 ±/± mice To assess whether introduction of MHCII into mhcii ±/± cd152 ±/± mice would restore B cell hyperactivity to the degree observed in mhcii +/+ cd152 ±/± mice, we generated male and female Ab0-DQ8.cd152 +/± mice (which do not express endogenous Fig. 2 . Spleen T cell populations in cd152 +/+ , cd152 +/± and cd152 ±/± mice. The indicated mice were sacri®ced at 3 weeks or 5 weeks of age and assessed for spleen CD3 + cells (panels A, D, G and J), spleen CD4 + cells (panels B, E, H and K) and spleen CD8 + cells (panels C, F, I and L). B6 mice are MHCII-intact; Ab0 mice are MHCII-de®cient; Ab0-DQ8 mice do not express murine MHCII but do express human MHCII (DQ8). int denotes cd152 +/+ genotype; het denotes cd152 +/± genotype; def denotes cd152 ±/± genotype. Each circle represents an individual mouse. The composite results are plotted as box plots. The lines inside the boxes indicate the medians; the outer borders of the boxes indicate the 25th and 75th percentiles; and the bars extending from the boxes indicate the 10th and 90th percentiles.
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at Pennsylvania State University on February 23, 2013 http://intimm.oxfordjournals.org/ Downloaded from murine MHCII but do express human DQ8). We mated them to each other, and the resulting F2 progeny was genotypically +/+, +/± and ±/± for cd152 at the expected 1:2:1 ratio. In 3-week-old Ab0-DQ8.cd152 ±/± mice, CD4 + cell expansion was more than completely restored (6-to 7-fold expansion relative to cd152 +/+ or cd152 +/± littermates; P < 0.001), and CD3 + and CD8 + cell expansions were preserved (3-to 4-fold expansion relative to cd152 +/+ or cd152 +/± littermates; P < 0.001 for each cell type) (Fig. 2G±I) . Importantly, DQ8.cd152 ±/± mice also manifested increased (~4-fold) splenic IgSC and increased (~4-fold) serum IgG levels in comparison to their CD152-suf®cient littermates (P < 0.001 for each) (Fig. 4L±M) . Taken together, these results demonstrate that B cell hyperactivity in cd152 ±/± mice occurs via both MHCII-dependent and MHCIIindependent pathways and that CD152 downregulates both pathways.
Discussion
Both CD4 + and CD8 + cells undergo marked activation and expansion in MHCII-intact cd152 ±/± mice with accompanying in®ltration of many vital organs (32±34). Similarly, many (MHCII-intact) humans treated with anti-CD152 mAb develop organ in¯ammation with in®ltration of CD4 + and/or CD8 + cells (47) . Moreover, the association of speci®c human autoimmune diseases with cd152 genetic polymorphisms (48) suggests that genetically determined differences in CD152 expression may affect susceptibility to clinical autoimmunity.
CD28-mediated signaling is vital to development of lymphoproliferation in MHCII-intact cd152 ±/± mice. Treatment of such mice with CTLA4-Ig (which blocks CD28/CD80 and CD28/ CD86 interactions) prevents their abnormal T cell activation and expansion for the duration of treatment (49) . Moreover, MHCII-intact cd152 ±/± mice that are also de®cient in CD80 and CD86 (cd80 ±/± cd86 ±/± genotype) are protected from the lymphoproliferative phenotype, but lymphoproliferation can be induced in these mice by arti®cial ligation of CD28 with an anti-CD28 mAb (50) . CD4 + cells also play a vital role in the lymphoproliferation that develops in cd152 ±/± mice. In contrast to the MHCIIrestriction exhibited by most CD4 + T cells, the great majority of CD8 + T cells are MHC class I-restricted. Nevertheless, their antigen-driven activation usually depends critically upon CD4 + cells (51±53). The fact that the massive expansion of CD8 + cells in MHCII-intact cd152 ±/± mice is largely prevented by treatment with a depleting anti-CD4 mAb (34) is consistent with this principle. Therefore, it was unexpected that despite substantially reduced numbers of CD4 + cells, CD8 + cell activation and expansion remained unabated in MHCII-de®-cient cd152 ±/± mice. The degree of CD8 + cell activation and expansion in these mice was similar to that in their MHCIIintact counterparts and in their counterparts expressing Fig. 3 . Activated CD4 and CD8 cells in cd152 +/+ and cd152 ±/± mice. Spleen cells from the indicated mice were triple-stained for surface CD4, CD44 and CD62L (top panels) or for surface CD8, CD44 and CD62L (bottom panels). The histograms illustrate CD4 and CD8 staining respectively, with the corresponding horizontal bars delimiting the CD4 + and CD8 + cells. The numbers across these bars indicate the percentages of cells staining positively for CD4 or CD8. The dot plots illustrate CD44 and CD62L staining for the CD4 + and CD8 + cell populations respectively. The numbers indicate the percentages of activated (CD44 + CD62L ± ) cells within the CD4 + or CD8 + populations.
human MHCII rather than murine MHCII (Figs 2 and 3) . Taken together, these observations strongly suggest that the helper role played by CD4 + cells in CD8 + cell activation can be dissociated from the ability of CD4 + cells to recognize antigen in the context of MHCII. Whether CD28-mediated signaling plays a role in MHCII-independent activation of CD8 + cells remains to be formally established.
Our results of unabated CD8 + cell expansion in MHCIIde®cient cd152 ±/± mice can readily be reconciled with the prevention of CD8 + expansion in anti-CD4-treated cd152 ±/± mice (34) . In the latter study, repeated injections of a depleting anti-CD4 mAb, beginning within 2 days after birth, had to be administered to cd152 ±/± mice over a 3-week period to effect continuous depletion of CD4 + cells. Without continuous CD4 + cell depletion, low numbers of activated CD4 + cells developed, and CD8 + cell expansion was not effectively blocked. Unfortunately, we could not similarly treat MHCIIde®cient cd152 ±/± mice with a depleting anti-CD4 mAb, since all MHCII-de®cient mice in our colony, regardless of cd152 genotype, do not tolerate repeated i.p. injections and succumb prematurely. Whether this intolerance to repeated i.p. injections is due to undue susceptibility to occult infections in MHCII-de®cient hosts or due to some other cause is uncertain.
Regardless, the great majority of the (MHCII-unrestricted) CD4 + cells in MHCII-de®cient mice bear an activated phenotype (Fig. 3) . Indeed, it may be that activated MHCII- Fig. 4 . Spleen B cells, spleen IgSC and serum IgG levels in cd152 +/+ , cd152 +/± and cd152 ±/± mice. The indicated mice were sacri®ced at 3 weeks or 5 weeks of age and assessed for spleen B (B220 + ) cells (panels A, D, G and K), spleen IgSC (panels B, E, H and L) and serum IgG levels (panels C, F, I and M). Presentation of the results is as in Fig. 2 . In panel J, serum IgG levels are plotted against spleen CD8 + cell numbers for the 9 individual mhcii ±/± cd152 ±/± mice tested. The solid line represents the calculated regression line. Alternatively, CD8 + cell activation and expansion in mhcii ±/± cd152 ±/± mice may be occurring by a pathway that altogether circumvents the requirement for antigen recognition by CD4 + cells. APC can be activated via engagement of their surface CD40 even in the absence of CD4 + cells (51±53). CD154 (CD40 ligand) can be expressed by both CD4 + and doublenegative (DN; CD4 ± CD8 ± ) CD1d-restricted T cells (54, 55) , so direct engagement of APC by CD154 + cells (even in an antigen-non-speci®c manner) could result in conditions permissive to activation and expansion of CD8 + cells. The reason that continuous depletion of CD4 + cells blocks CD8 + cell expansion in cd152 ±/± hosts may have nothing to do with MHCII/CD4 + cell interactions but may be consequent to the elimination of most CD154 + cells. MHCII-de®cient mice may have suf®cient numbers of CD154 + cells to activate APC and permit unabated CD8 + cell activation and expansion. Experiments utilizing CD154-de®cient mice should help clarify this point. In any case, our ®ndings clearly point to a vital downregulatory role for CD152 in MHCII-independent activation and expansion of CD8 + cells.
MHCII-independent expansions in CD152-
In vivo de®ciency of CD152 leads not only to marked activation and expansion of T cells, but it also leads to marked increases in IgSC and circulating Ig levels (Fig. 4) . Of note, numbers of splenic B (B220 + ) cells are not increased in cd152 ±/± mice despite the increased in vivo Ig production in such mice. This may re¯ect a preferential downregulatory effect of CD152 on differentiation, rather than on proliferation, of B cells. Alternatively, B cell numbers may truly increase in cd152 ±/± mice, but the expanded B cells may preferentially home to extrasplenic sites. Increased numbers of lymph node B cells have been described in cd152 ±/± mice (34) , and other sites, such as the intestine or bone marrow, may also harbor increased numbers of B cells.
In either case, the observed B cell hyperactivity in cd152 ±/± mice is effected via both MHCII-dependent and MHCIIindependent pathways. In mhcii ±/± cd152 ±/± mice, B cell hyperactivity is not apparent at 3 weeks of age but is readily apparent at 5 weeks of age (Fig. 4) , demonstrating MHCIIindependent B cell hyperactivity in the absence of CD152. Introduction of a transgene for human DQ8 into cd152 ±/± mice de®cient for murine MHCII (but now expressing human MHCII) restores the vigorous B cell hyperactivity (Fig. 4) , demonstrating superimposed MHCII-dependent B cell hyperactivity in the absence of CD152.
Of note, splenic IgSC numbers were essentially identical in MHCII-de®cient cd152 +/+ or cd152 +/± mice compared to those in the corresponding MHC-intact mice (compare Fig. 4E with  B) . This strongly suggests that B cell maturation to the IgSC state can occur normally in the absence of MHCII. A component of this B cell maturation may be T cell-independent, but it is likely that there is also a T cell-dependent component. Although serum IgG levels were lower in MHCIIde®cient cd152 +/+ or cd152 +/± mice compared to the respective levels in the corresponding MHC-intact mice (compare Fig. 4F with C), serum IgG levels had dramatically increased in the majority of MHCII-de®cient cd152 ±/± mice by 5 weeks of age (Fig. 4I) . Importantly, serum IgG levels in these mice correlated strongly with the degree of CD8 + cell expansion (Fig. 4J) , raising the possibility that a component of the MHCII-independent B cell hyperactivity in mhcii ±/± cd152 ±/± mice is driven by CD8 + cells. It may be that optimal treatment of autoimmune disorders associated with B cell hyperactivity may require targeting not just B cells and CD4 + cells but CD8 + cells as well.
